GGHC
NVLN

Gilder Gagnon Howe & Co’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-21,833
Closed -$202K – 307
2017
Q2 		$202K Sell
21,833
-309,766
-93% -$2.98M ﹤0.01% 247
2017
Q1 		$3.56M Buy
331,599
+71,409
+27% +$730K 0.06% 155
2016
Q4 		$2.19M Buy
+260,190
New +$2.3M 0.04% 158

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Gilder Gagnon Howe & Co's NVLN Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2017, closing a stake of 21,833 shares — an estimated $202K sold.

Gilder Gagnon Howe & Co first reported a position in NVLN in Q4 2016 and held it in 3 quarters. The position peaked at $3.56M in Q1 2017. 72 funds tracked by Wall St. Rank hold NVLN as of Q3 2017.

  • Gilder Gagnon Howe & Co reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 21,833 Novelion Therapeutics Inc. Common Shares shares in Q3 2017, an estimated $202K.
  • Gilder Gagnon Howe & Co first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Novelion Therapeutics Inc. Common Shares position peaked at $3.56M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.